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Abstract Bruton tyrosine kinase (Btk) plays a crucial role in
the differentiation of B lymphocytes and belongs to the group of
Tec kinases, which are characterised by the presence of a
pleckstrin homology domain. Here we show that Btk is activated
and undergoes tyrosine phosphorylation upon challenge of
platelet thrombin receptor, these responses requiring engagement
of KIIb/L3 integrin and phosphoinositide 3-kinase activity. These
data unravel a novel signalling pathway involving Btk down-
stream of an adhesive receptor via a complex regulation
implicating the products of phosphoinositide 3-kinase, which
might act to anchor Btk at the membrane.
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1. Introduction
Platelets play a key role in haemostatic reactions and are
activated by numerous agonists, including thrombin. Upon
cleavage of its seven-transmembrane domain receptor, throm-
bin induces three successive waves of tyrosine phosphoryla-
tion involving several non-receptor protein tyrosine kinases
(PTK) [1]. Recently, a new subfamily of cytoplasmic PTK
that share sequence homology with Src has been identi¢ed.
They include Bruton tyrosine kinase (Btk), Itk, Tec and Bmx
[2]. In addition to the catalytic, Src homology 2 (SH2) and
SH3 domains, Btk has a characteristic N-terminal region con-
sisting of a pleckstrin homology (PH) domain and a proline-
rich region referred to as the tec homology (TH) domain [3].
These kinases are predominantly expressed in the haemato-
poietic lineage, but Tec and Bmx seem to be more ubiquitous.
Btk, which is particularly present in B lymphocytes, is acti-
vated by stimulation of interleukin receptors [4], IgE receptor
(FcORI) [5], and B cell receptor [6]. Btk de¢ciency results in
human and murine genetic disorders such as X-linked agam-
maglobulinaemia, indicating that this kinase plays an impor-
tant role in B-cell di¡erentiation [3,7].
Btk can also be activated by Gq protein K subunit [8], while
a direct activation of both Btk and Itk by G protein LQ sub-
units has been observed in vitro [9]. In addition, the N-termi-
nus of the PH domain of Btk has been shown to bind with
high a⁄nity to inositol 1,3,4,5-tetrakisphosphate and (or)
phosphatidylinositol 3,4,5-trisphosphate [10^13], this kind of
interaction promoting association of Btk with the plasma
membrane [13]. These data suggest that the PH domain of
Tec kinases might be critical for their activation. Moreover,
the PH domain of Btk is able to interact with several isoforms
of protein kinase C (PKC), causing a decrease of its tyrosine
kinase activity [14]. This observation contrasts with the pos-
itive e¡ects of PKC described for another PTK from the Tec
family (Itk) speci¢c to T lymphocytes [15]. If the role of PKC
in the modulation of PH domain-containing PTK seems to be
yet unclear, the implication of the Src kinase family in stim-
ulating the enzymatic activity of Btk is now well documented
and involves complex interactions between the proline-rich
sequence of Btk TH domain and the SH3 domain of Src
kinases [16,17].
In this study, we provide evidence that this PH domain-
containing PTK is present in platelets, and participates in a
signalling pathway occurring downstream of integrin KIIb/L3.
We also show that phosphoinositide (PI) 3-kinase is involved
in both the activation of Btk and its translocation to the
membrane of activated platelets.
2. Materials and methods
2.1. Materials
Human thrombin, thrombin-receptor activating peptide (TRAP),
tetrapeptide RGDS, wortmannin, protein A-Sepharose, glutathione-
Sepharose, anti-mouse and anti-rabbit IgG horseradish peroxidase
conjugate were purchased from Sigma. A polyclonal antibody directed
against the PH+TH domain of Btk was obtained by injecting a rabbit
with the fusion protein GST-Btk (1^216). Anti-phosphotyrosine
monoclonal antibody 4G10 was from Upstate Biotechnology Inc.
(Euromedex, Strasbourg, France). [Q-32P]ATP (3000 Ci/mmol) was
from Amersham (Les Ulis, France). The enhanced chemiluminescence
SuperSignal Western blotting substrate was obtained from Pierce (In-
terchim, Montluc°on, France).
2.2. Incubation of platelet suspensions and Btk immunoprecipitation
Platelet suspensions (1U109 cells/ml) in Tyrode’s bu¡er containing
albumin but lacking calcium were prepared from human platelet con-
centrates (Etablissement de Transfusion Sanguine PyreŁneŁes-Garonne,
France) as previously described [18,19]. In some experiments, platelet
suspensions (500 Wl) were incubated with either RGDS (500 WM),
RGES (500 WM), or wortmannin (10 or 100 nM) for 20 min before
addition of TRAP (10 WM). Incubations were terminated by addition
of 250 Wl of lysis bu¡er thus achieving the following ¢nal concentra-
tions: Tris-HCl, pH 8.0, 20 mM; NaCl, 150 mM; EDTA, 2 mM;
Triton X-100, 1% (v/v); sodium dodecyl sulphate (SDS), 0.2% (w/v);
Na3VO4, 1 mM; aprotinin, 10 Wg/ml; leupeptin, 10 Wg/ml; phenyl-
methylsulphonyl £uoride, 1 mM; sodium pyrophosphate, 5 mM.
After standing on ice for 15 min, the lysates were sonicated (twice
for 20 s) and centrifuged (12 000Ug for 10 min at 4‡C) to remove
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insoluble material. The clear lysates (700 Wl) were incubated for 30
min with 40 Wl of a 10% suspension of protein A-Sepharose and
centrifuged as above. The supernatants were then incubated for 2 h
at 4‡C with rabbit polyclonal anti-Btk antibody, followed by addition
of 80 Wl of a 10% suspension of protein A-Sepharose for 1 h at 4‡C.
The immunoprecipitates were then collected by centrifugation
(6000Ug for 5 min at 4‡C), washed ¢ve times in lysis bu¡er and
solubilised in Laemmli’s sample bu¡er for polyacrylamide gel electro-
phoresis [20].
2.3. In vitro kinase assay of Btk
Clari¢ed whole lysate from 500 Wl platelet suspension was used for
immunoprecipitation as described above, except that SDS was omit-
ted. The immune complex was washed twice in lysis bu¡er and twice
again in 50 mM Tris-HCl (pH 7.4) containing 0.5 mM Na3VO4. The
kinase reaction was carried out for 20 min at 30‡C under shaking in
40 Wl of kinase bu¡er (50 mM Tris-HCl, pH 7.4, 2.5 mM MgCl2 and
5 mM MnCl2) containing 10 WM ATP, 10 WCi [Q-32P]ATP and 10 Wg
of GST-PLCQ1. The latter fusion protein contained amino acids 538^
780 of PLCQ1, including the two SH2 domains as well as phosphoryl-
atable tyrosine residues 771 and 775. In some experiments a truncated
GST-PLCQ1 (amino acids 538^757) was also used. To better deter-
mine the substrate speci¢city of Btk, another fusion protein (GST-
HS1) containing HS1 peptide (amino acids 388^403), which is specif-
ically phosphorylated by Syk tyrosine kinases, was used in some
experiments.
2.4. Detection of Btk translocation to the platelet membrane
Washed platelets (7.5U108/ml) were activated by TRAP (10 WM)
after a previous incubation (20 min at 37‡C) in the absence or in the
presence of wortmannin (10 or 100 nM). Reactions were stopped by
addition of one volume of twice concentrated ice-cold bu¡er I, which
contained 50 mM Tris (pH 7.4), 200 mM KCl, 6 mM ATP, 6 mM
MgCl2, 10 mM benzamidine, 10 Wg/ml leupeptin, 10 Wg/ml aprotinin,
2 mM phenylmethylsulphonyl £uoride and 0.2 mM Na3VO4. All sub-
sequent steps were performed at 4‡C. Cells were sedimented immedi-
ately by centrifugation at 12 000Ug for 20 s, resuspended in 600 Wl of
bu¡er I, and sonicated four times for 10 s. The membrane fraction
was isolated by centrifugation at 120 000Ug for 40 min. Membranes
were washed once with 100 Wl of bu¡er I, then suspended in 500 Wl of
bu¡er I for protein determination using a Bio-Rad assay system, and
15 Wg of protein from each sample were analysed by Western blotting
using anti-Btk polyclonal antibody.
2.5. Protein electrophoresis and immunoblotting
Immunoprecipitates were boiled with 20 Wl of Laemmli’s sample
bu¡er, proteins were separated on an 8% polyacrylamide gel in the
presence of SDS under reducing conditions [20], transferred to nitro-
cellulose membranes and checked by immunoblotting essentially as
described in [18,21], using the enhanced chemiluminescence system.
3. Results
3.1. Platelet Btk is tyrosine phosphorylated and activated upon
thrombin stimulation
In order to examine whether Btk is implicated in thrombin
signalling, human platelets were stimulated for various peri-
ods of time with TRAP (10 WM) and the tyrosine kinase was
immunoprecipitated. Western blotting with anti-phosphotyro-
sine antibody showed that Btk was slightly phosphorylated at
10 s, tyrosine phosphorylation reaching a maximum at 3 min
of stimulation (Fig. 1A). It was veri¢ed that equal amounts of
Btk were recovered in the immunoprecipitates (Fig. 1B), and
that no signal was detected with immunoprecipitates obtained
with non-immune serum (not shown).
We also tested whether TRAP stimulation would increase
Btk activity using an immune complex kinase assay. Tyrosine
phosphorylation of Btk was correlated with a signi¢cant in-
crease in its activity, detected using GST-PLCQ1 (538^780) as
an exogenous substrate, maximal activity (2.05 þ 0.26-fold in-
crease) being observed after 3 min of thrombin stimulation
(Fig. 1C). As a control, GST-PLCQ1 (538^757), which lacks
tyrosine residues 771 and 775, was not phosphorylated by Btk
(Fig. 1D). Moreover, this Btk activity appeared to be sub-
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Fig. 1. Time course of Btk tyrosine phosphorylation and activation in thrombin-stimulated platelets. Platelets (5U108) were stimulated with
TRAP (10 WM) for the indicated times and subjected to immunoprecipitation (IP) as described in Section 2. Immunoprecipitates were analysed
by anti-phosphotyrosine immunoblotting (A). The level of immunoprecipitated Btk was revealed by immunoblotting (IB) using anti-Btk anti-
body (B). Immunoprecipitates were subjected to an immune complex kinase assay using as a substrate GST-PLCQ1 (538^780), which contains
the two SH2 domains as well as tyrosine residues 771 and 775 (C). In some experiments, this substrate was replaced by a fusion protein (GST-
PLCQ1 538^757) lacking the two phosphorylatable tyrosine residues (D) or by GST-HS1 (E). Radiolabelled proteins were separated by SDS-
PAGE and visualised by PhosphorImager scanning. Data are representative of three experiments. NRS, normal rabbit serum.
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strate-speci¢c since GST-HS1, which was shown to be a good
substrate for Syk at tyrosine 397 [22], was not phosphorylated
by Btk (Fig. 1E).
3.2. Btk tyrosine phosphorylation and activation are coupled to
integrin KIIb/L3 engagement
Addition of RGDS to thrombin-stimulated platelets abol-
ished aggregation by preventing ¢brinogen binding to integ-
rin. This treatment inhibited by 76 þ 5% Btk tyrosine phos-
phorylation occurring at 3 min of thrombin stimulation (Fig.
2A,B). Moreover, when platelet aggregation was prevented by
the absence of shaking during stimulation, Btk tyrosine phos-
phorylation was also strongly reduced (Fig. 2C). In addition,
TRAP-induced activation of Btk was inhibited by 74 þ 9% by
RGDS, whereas RGES was without signi¢cant e¡ect (Fig. 3).
These data clearly indicate that Btk phosphorylation is de-
pendent on platelet aggregation via integrin KIIb/L3 engage-
ment.
3.3. PI 3-kinase is involved in thrombin-induced activation and
membrane association of Btk
The stimulation of Btk activity promoted by TRAP (10
WM) was reduced by 57 þ 8% when platelets were preincu-
bated with 10 nM wortmannin (Fig. 3). As shown in Fig. 4,
TRAP (10 WM) promoted the translocation of Btk to the
platelet membrane, which reached around 4 times the basal
level after 1 min of stimulation. Membrane association of Btk
promoted by TRAP was decreased by 66 þ 12% or 94 þ 8% in
the presence of 10 or 100 nM wortmannin, respectively (Fig.
4). These results indicate that PI 3-kinase products are ac-
tually involved in the translocation of Btk to the membrane
of activated platelets.
4. Discussion
From our investigation, it is obvious that Btk is present in
signi¢cant amounts in platelets and appears to participate in
the signalling pathways evoked upon activation of thrombin
receptor. Btk tyrosine phosphorylation and activation ob-
served herein appear mainly as secondary events related to
integrin KIIb/L3 engagement, since they are inhibited when
aggregation is suppressed by competing for ¢brinogen binding
to its receptor. These results indicate that Btk is not restricted
to immunocompetent cells [3^7] and might also be involved in
cell signalling evoked by adhesion receptors, the data reported
herein representing the ¢rst example of such a possible link
between Btk and integrins. We and others have also previ-
ously described the same relationship between another PH
domain-containing tyrosine kinase (Tec) and platelet KIIb/L3
integrin [23,24].
Platelets constitute a very useful model to delineate a num-
ber of signalling events evoked by integrin engagement and
(or) its immediate functional consequence, i.e. platelet aggre-
gation. These include Ca2 in£ux [25] and various tyrosine
phosphorylations possibly involving Src kinases, Syk or the
focal adhesion kinase pp125FAK [26,27]. It is thus tempting to
speculate upon which of the signalling events occurring down-
stream of integrin KIIb/L3 could be related to the tyrosine
phosphorylation and activation of Btk. Two of them deserve
some discussion and include Src kinases and PI 3-kinase.
Several reports have shown that the activation loop for
tyrosine phosphorylation of Btk is generated by a combina-
tion of the activities of both Src kinases and Btk itself [16,17].
Indeed, the SH3 domain of Src kinases is able to bind to the
TH domain of Btk [28]. This binding is followed by tyrosine
phosphorylation of Y551 in the Btk catalytic domain. This
transphosphorylation by Src kinases leads to an increase in
the catalytic activity of Btk and to autophosphorylation at the
second site present in its SH3 domain [29,30]. In platelets,
pp60src is activated early after thrombin stimulation, possibly
leading to Btk tyrosine phosphorylation. This would be anal-
ogous to the process already described for Btk activation in B
cells upon antigen stimulation, since Lyn and Blk are stimu-
lated within seconds after B cell receptor activation, Btk phos-
phorylation occurring later on at 5 min [31]. In the same way,
Li et al. [32] have shown a correlation between membrane
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Fig. 2. Btk tyrosine phosphorylation is dependent on integrin KIIb/L3 engagement and on platelet aggregation. Platelets (5U108) were stimulated
for the indicated times with thrombin (1 NIH unit/ml) with (A and B) or without (C) shaking. In B, platelets were preincubated with RGDS
(500 WM). Lysates were subjected to immunoprecipitation with anti-Btk antibody and analysed by antiphosphotyrosine immunoblotting (IB:
pY, upper panel). After stripping, the level of Btk protein was revealed by immunoblotting (IB: Btk, lower panel). Three experiments were per-
formed with the same conclusions.
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targeting and an increase of Btk tyrosine phosphorylation,
suggesting that Btk may have to be placed in the vicinity of
a Src kinase to become activated.
In this context, the fact that thrombin stimulation promotes
translocation of Btk to the membrane is particularly interest-
ing to consider. This phenomenon has been already reported
by Kawakami et al. [5] in mast cells stimulated by IgE. Some
membrane phospholipids, essentially the products of PI 3-ki-
nase, might be involved, as suggested by the e¡ect of wort-
mannin. Since a speci¢c interaction between the PH domain
of Btk and phosphatidylinositol 3,4,5-trisphosphate has been
reported, it is tempting to suggest that the products of PI
3-kinase might play a crucial role in the behaviour of Btk
observed in thrombin-stimulated platelets. Our observations
are in agreement with previous studies describing similar
speci¢c interactions between PI 3-kinase products and Btk
or Itk in immunocompetent cells [12,13,33,34]. Similar inter-
actions also occur between a serine/threonine kinase bearing a
PH domain (Akt) and PI 3-kinase products [35]. However, it
is still di⁄cult to conclude whether the inhibitory e¡ect of
wortmannin on Btk activation is due to the lack of Btk trans-
location or to the fact that wortmannin inhibits KIIb/L3 in-
tegrin and platelet aggregation [36].
In most examples described so far, Btk tyrosine phospho-
rylation is accompanied by activation of its kinase activity
[16,17], which we also observed in platelets. However, it still
remains to identify speci¢c substrates of Btk. To date, only
PLCQ2 was found to be tyrosine phosphorylated and activated
by Btk in B lymphocytes [37]. This is in agreement with the
fact that PLCQ1 appeared as a selective substrate of Btk in our
in vitro kinase assay.
During the preparation of this article, it was reported that
Btk is tyrosine phosphorylated in collagen- and thrombin-
treated platelets, only collagen response being altered in pa-
tients lacking Btk [38]. This led the authors to suggest that
Btk is not essential in the mechanism of platelet activation by
thrombin. If this is true for the primary events evoked down-
stream of platelet thrombin receptor, the present study brings
evidence that Btk is activated in the signalling pathway
evoked by an integrin. This should stimulate further studies
dealing with other PTK of the Tec family and in other cells
than platelets, where adhesive events are known to play an
important role in signalling pathways regulating cell prolifer-
ation.
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Fig. 4. E¡ect of wortmannin on Btk translocation to the platelet
membrane. Platelet suspensions were preincubated or not for 10
min at 37‡C with 10 nM or 100 nM wortmannin (Wort), followed
by addition of TRAP (10 WM) and further incubation for the indi-
cated times. At the end of the incubations, the platelet membrane
was isolated as described in Section 2 and probed for the presence
of Btk by immunoblotting. A typical immunoblot is shown in A,
whereas B presents results of immunoblot quanti¢cation. Data
(stimulation fold compared to non-activated control platelets) are
means þ S.E.M. of three di¡erent experiments.
Fig. 3. PI 3-kinase and KIIb/L3 integrin are involved in Btk activa-
tion by TRAP. A: Platelets (5U108) were preincubated for 20 min
in the absence of inhibitors (lanes 1^3), with 10 nM wortmannin
(Wort, lane 4), 500 WM RGDS (lane 5) or 500 WM RGES (lane 6)
before addition of 10 WM TRAP (lanes 3^6) or 1 NIH unit/ml of
thrombin (Thr, lane 2) and further incubation for 3 min at 37‡C. In
vitro kinase assay of Btk was performed using GST-PLCQ1 (538^
780) as a substrate. Proteins were separated on a 10% polyacryla-
mide gel and radioactivity was detected with PhosphorImager. The
data shown are representative of four di¡erent experiments with
identical results. B: The radioactivity of the substrate was quanti¢ed
using Imagequant program and data (means þ S.E.M., n = 4 experi-
ments) are expressed as fold increase of Btk activity. **P6 0.01,
probability of signi¢cance according to Student’s t-test; ns, non-sig-
ni¢cant.
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